• One Health
  • Pain Management
  • Oncology
  • Anesthesia
  • Geriatric & Palliative Medicine
  • Ophthalmology
  • Anatomic Pathology
  • Poultry Medicine
  • Infectious Diseases
  • Dermatology
  • Theriogenology
  • Nutrition
  • Animal Welfare
  • Radiology
  • Internal Medicine
  • Small Ruminant
  • Cardiology
  • Dentistry
  • Feline Medicine
  • Soft Tissue Surgery
  • Urology/Nephrology
  • Avian & Exotic
  • Preventive Medicine
  • Anesthesiology & Pain Management
  • Integrative & Holistic Medicine
  • Food Animals
  • Behavior
  • Zoo Medicine
  • Toxicology
  • Orthopedics
  • Emergency & Critical Care
  • Equine Medicine
  • Pharmacology
  • Pediatrics
  • Respiratory Medicine
  • Shelter Medicine
  • Parasitology
  • Clinical Pathology
  • Virtual Care
  • Rehabilitation
  • Epidemiology
  • Fish Medicine
  • Diabetes
  • Livestock
  • Endocrinology

PRODUCT NEWS: Nocita Now Labeled for Declaw Surgery Pain Relief

Article

Nocita is now approved to provide up to 72 hours of pain relief for cats following onychectomy.

Aratana received FDA approval for Nocita (bupivacaine liposome injectable suspension) in August 2016 as pain relief for canine patients following cranial cruciate ligament surgery. On Friday, the label was expanded to include postoperative pain relief for up to 72 hours for cats undergoing onychectomy.

“We believe veterinarians are in need of safe and effective, non-opioid alternatives to provide pain relief to their feline and canine patients,” Aratana Chief Development Officer Ernst Heinen, DVM, PhD, said.

RELATED:

  • Tug of War: Ethical Decision-Making in Veterinary Medicine
  • Declawing Cats: Adverse Medical and Behavioral Outcomes

Nocita should be much more widely adopted in cats once the company is able to manufacture the product in smaller, 10-mL vials. According to Aratana CEO Steven St. Peter, MD, manufacturing of these smaller vials is slated for fall 2019.

The company is also hoping to expand the label indication for Nocita to include additional surgical procedures in dogs and cats. "As we continue to see sequential growth, we do believe that there is significant potential in the Nocita franchise," Dr. St. Peter said.

For full prescribing information, visit the Aratana website.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.